Annovis Bio Inc (ANVS)

$ANVS 4$ potentially

$ANVS https://www.sciencedaily.com/releases/2025/10/251022023113.htm Anvs's SAB guy's laboratory.

$ANVS Dear Ms. Forest Foxes, would you please share a link to your children's book (if you like), we want to read it. We are truly interested. @ForestFoxes @BIG_BEAR_ 👇

$ANVS lots of drama here. Let’s cut the crap. Most likely this company will fail BUT there will indeed be a run up before data releases because at this market cap there is indeed asymmetric upside. Any timelines we got to work with ? I will consider a long position when appropriate. No shorting here as it’s too risky. @ForestFoxes you seem like the expert here, what’s the timeline?. Maybe also throw out a link to your children’s book so we can educate the bears here on Alzheimer’s ?

$NWBO $ANVS Hello old friends still holding the two tagged . My Tree Nursery took off . Needed something to do , and fortunately making some dinero to travel. My pomegranate Orchard reached 500 trees and called it enough. 3rd year at it Ok here’s the closest to bitcoin of come . Seen D.jr post something on his X account beginning of the week and bought some shares . Hope you’re all doing good . Miss the early days with all of you

$GOOGL Continuing to save my portfolio from catastrophic losses incurred by $ANVS 🤝

$AVXL is being tagged because of a request towards the end of this post. --------------------------------- With sincerity and based on my direct observations and personal experiences, I would have to disagree with you about Dr. Maccecchini, CEO of $ANVS @_Julia because she is factually not a competent leader. She does NOT follow SEC compliance, does not issue truthful material information which shareholders and prospective investors alike base their decisions on, does not listen to her attorneys, has stated on the record she does not follow the advise of her Board of Directors, does not adhere to proper business conduct such as abiding by contracts that she has entered into, attacks and/or uses employees and contractors as excuses, and give patients and their families false hopes. This issue can not be set aside as long as Dr. Maccecchini continues to abuse patients and shareholders alike. The demonstratives/exhibits that I have been sharing are images and transcripts of Dr. Maccecchini. None of the statements have been fabricated. Dr. Maccecchini’s nefarious conduct goes beyond what I am able to publicly share. I assume that you are responding to my post from earlier this evening. What parts of attached images 2, 3 and 4 are not accurate? -- On the 2nd image, she did tell investors that multiple foreign nations would support her and that this was "low hanging fruit". -- On the 3rd image she did cite figures such as 12M, 50M, 14M, over 200M mentioning "we feel very comfortable that we have the money" when the truth is that funds are only possible from duping patients, investors, and forming relationships with Vulture Funds. -- The 4th image is one of the worst and most offensive because Dr. Maccecchini is poaching patients and their families hard earned money with false hopes. That event titled, "Annovis Patients' Live Forum" back load with planted callers. I witnessed this firsthand and captured many screen images of these callers with transcripts. https://stocktwits.com/ForestFoxes/message/633534560 Julia, your comment on Sep 06, 2025 to @kgw567 mentions the "strange idea" of a children's book. kgw567 continues to make insulting post about me. I would like to clear the air about this. I am an investor, just like you are. I believed in Dr. Maccecchini and since 2021 had been supporting her with corrections and retractions of some of her public materials. Some of the PRs you have seen are a result of my direct work. I have had hundreds of interactions with her. She attacks people. I have shared examples of her attacking authors and even an investor. Can you imagine the possibility that she might direct others to do this on her behalf since she herself is willing to do this??? Julia, you and kgw567 made comments about my "children's book". Your comments were based on wild guesses. Either of you could have simple asked me why that work was done. Instead, you created an atmosphere of animosity. This is not what I want among shareholders. I don't post to hurt shareholders. I post to protect others, which includes patients, their families, and prospective new shareholders since Dr. Maccecchini clearly has them in her crosshairs. Her recent PR earlier this month is just one example. --------------------------------- Does anyone have the video from Dr. Marwan Sabbagh explaining the mechanism of action for blarcasmesine? The link that I shared with Dr. Maccecchini is now showing a "404" code which means that the page doesn't exist anymore. It was a very good video. I told Dr. Maccecchini that, "This 6:04 minute presentation has many benefits and could be considered a benchmark for Annovis to produce when time and resources are available. As we’ve come to understand, many investors are not able to articulate how buntanetap works. I’m not even sure it’s an issue of being able to articulate/describe how it works as opposed to actually not fully understanding it. Providing an understandable video empowers investors to have the conviction based on science that they DO understand." (This paragraph was just a snippet of my conversation with Dr. Maccecchini.) I'm not going to directly say that Dr. Maccecchini thinks that blarcasmesine doesn't stand a snowflakes chance in Hell as I don't want to put words in her mouth. However, she did seems quite fond of using the word "Hell" repeatedly during her "Patients' Live Forum" which I found incredibly disrespectful. She is also quite clear with this statement that her drug, buntanetap, is "900% confidently" more effective than any other drug (which of course would include Anavex's) via this statement: "At this point our drug looks more promising than any Alzheimer drug on the market or in development" Source: https://stocktwits.com/MaccM/message/606412928 @MayoMobile has seen my animated "children's book" as you refer to it, Julia. Jesse, do you by chance have the video link to Dr. Marwag's explanation? I'll let you decide for yourself, Julia, whether Dr. Maccecchini is being disrespectful to Dr. Marwag 🤔 Is she being disrespectful to you and other shareholders because she thinks that her easy-peasy explanation of how buntanetap works ... works better for emptying your purse? Note: This conversation only scratches the surface of what I have witnessed. IMO, patients and shareholders have been mislead and continue to be. #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #GoTeamFox #Parkinsons #Research #FindACure #UnityWalk #OutrunPD #NIH #NIA #SEC #DrMarwanSabbagh

Wait ... you mean the CEO of $ANVS Dr. Maccecchini is not a liar??? What?!? I don't have too much time on my hands, but I do have enough time to take a few minutes to draft this quick post. If I had more time the post would be ginormous 🤥👐 This writeup represents just the ... "Low Lying FruitFruit 🍌" 😂 Synopsis: Dr. Maria Maccecchini’s Pattern of False Promises and Investor Misrepresentation Across multiple public forums between June 2024 and February 2025, Dr. Maria Maccecchini, CEO of Annovis Bio, repeatedly made unverified, exaggerated, and financially misleading claims about the company’s partnerships, funding, and clinical readiness—creating a pattern of false assurances to investors and patients. (1) Virtual Investor Presentation – June 18, 2024: “Annovis Bio's Breakthroughs in Alzheimer’s and Parkinson’s” During this investor pitch, Dr. Maccecchini suggested imminent international Phase 3 trials and partnerships despite no supporting regulatory approvals or signed collaborations. She claimed: “Easier to do is to partner with a country and then do a joint venture in that country ... Japan 🇯🇵 we would do the same Phase 3 ... in the United States 🇺🇸 ... we can do the same with China 🇨🇳 we can do the same with ... probably not Russia 🇷🇺 (because Dr. Maccecchini has morals) ... but, with a country in Europe 🇪🇺 or a country in whatever ... I can’t be too specific because that is the low-hanging fruit.” 🍌🍌🍌 The assertion implied multiple global Phase 3 partnerships were within reach, yet no subsequent filings, agreements, or official disclosures confirmed any such deals. Analysts later noted that no joint ventures or Phase 3 sites outside the U.S. were ever initiated, making the statement a false promise of near-term expansion. (2) Annovis Year-End Investor Webcast – December 11, 2024 Dr. Maccecchini made bold and financially misleading claims about Annovis Bio’s funding capacity, asserting that the company was “ready to go” with over $200 million in available capital, despite SEC filings showing far less liquidity. She stated: “We’re ready to go of course the 12M ... we just put in place a 50M ATM facility that will help us ... have raised a total of 14M from the existing ELOCK and we’re planning to draw down another 30M so between the ... are over 200M ... we feel very comfortable that we have the money ... anywhere between the end of the year and April so you will hear shortly how we’re getting the 200M ... or, partnership, so the simple answer is yes, yes, yes, yes, yes.” This statement gave investors the false impression that Annovis was fully funded for Phase 3 trials and operations, even though subsequent filings and cash flow data revealed severe financial strain and dilution. The vague “yes, yes, yes, yes, yes” refrain served to reinforce investor confidence without substantiation, a hallmark of deceptive financial communication. (3) Annovis Patients’ Live Forum – February 27, 2025 In a session intended for patients and caregivers, Dr. Maccecchini made an ethically questionable and manipulative appeal, directly urging attendees to purchase stock: “Buy stock! It’s the ONLY way out!!!” This statement blurred the line between scientific outreach and financial solicitation, exploiting patient trust. It suggested that the company’s success—and implicitly, their loved ones’ hope—depended on stock purchases, a tactic viewed as highly inappropriate and misleading under securities and medical ethics standards. #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #GoTeamFox #Parkinsons #Research #FindACure #UnityWalk #OutrunPD #NIH #NIA #SEC P.S. Annovis Bio has done Maxim Group events before including this one from 2021. IMO, none of these events will advance "her story" which is based on her as an Under Dog ... albeit one with "900% confidence" her drug works!!! But, with NO robust proof 👈🤨🚩

$ANVS Interesting that Michael presented at the Maxim conference as opposed to Maria.

$ANVS 84 total clinical sites 75 clinical sites recruiting 9 clinical sites not yet recruiting

$ANVS swing to $7.00

Behind the Scenes at $ANVS ... No Retail investor on this channel has come forth, at least that I know of, that has been invited into the company and witnessed what Annovis Bio focuses on. This matters because we are all sharing our observations based on publicly available information, however I don't have any fellow investors to compare notes with regarding observations from the inside. This mean that what I share on this channel is fact-based (emails, notes from calls and video, etc.) as opposed to publicly released information. However, I have also noticed that I have collected more material public information than many others as I tried to maintain situational awareness on the company for its behalf. I now share my findings to ensure that people are not being deceived or misdirected. This is a burden. If I only knew what you all knew I might be continuing to share many your opinions ... and, perhaps your enthusiasm. But, having seen behind the curtains I no longer have that luxury of cheering for the company. This flag 🏁 has been replaced with this flag 🚩 A lot of them 🚩🚩🚩🚩🚩 .. .... 🚩🚩🚩🚩🚩🚩🚩🚩 IMO, Dr. Maccecchini doesn't design drug trials which confirm with any efficacy robustly. Entities in this space know this. Retail investors do not. Dr. Maccecchini is knowledgeable enough to know the check boxes required for writing ✍️ up and getting patients approved. She's also gifted/creative enough to generate just enough vague data with her drug studies to get a Phase 3 Alzheimer study approved by the FDA. This is the same with her Parkinson's work. As a scientist focused in this area, she knows that Parkinson's disease can improve with the placebo effect, and studies have shown significant motor symptom improvement in up to 50% of patients who received a placebo. This is largely due to the brain's release of its own dopamine, a chemical that is reduced in Parkinson's, in response to the expectation of benefit from treatment. The effect can influence various symptoms, including tremor, stiffness, and gait, and is a crucial factor to consider in clinical trials for new Parkinson's therapies. The placebo effect is a major reason why clinical trials use rigorous methods like double-blinding, patient screening, sufficient trial size, etc. Controlling for expectations: Understanding the placebo effect allows researchers to better determine the true, additional benefit of a new drug or therapy beyond what can be achieved through expectation alone. With the way Annovis Bio is run under the leadership of Dr. Maccecchini this dynamic is inverted. Expectations are at the forefront of patients, their families, and investors. IMO, Dr. Maccecchini sells hope 🐍🚩 🌈 "The placebo effect is typically a good response -- less tremor or stiffness, better sleep or improved mood." Efficacy has NOT yet been established despite Dr. Maccecchini's repeated claims that she is "900% confident that the drug works". Buntanetap, formerly known as Posiphen or ANVS401 has been animal tested over a dozen times for safety. This helps ensure that drug trial patients do not get severe adverse effects from the drug. However, it does NOT prove that the drug works. 🦄 Annovis Bio's data does NOT possess scientific defensibility or clinical utility. As such, comments from patients such as these although create hope, don't matter on a science basis regardless of whether the patients were on buntanetap or not. Patients on placebos may ALSO have a high likelihood of improvements or joy in life! This is great from the standpoint a feel good event. However, Dr. Maccecchini uses this as selling points ... points that NO entities with capital specializing in this field remotely believes. #NoOneShowsUpForScheduledInvestmentMetAndGreets -- I was in a blind trial in which after its conclusion, i was told I had the 20mg dosage. The drug worked really well ! 0 side effects -- I'm not only an investor, I am also a patient who benefitted from the drug during the trial.. It works guys at least it did for me. Early parkinsons 1yr 5 months. Improved arm swings less generall rigidity and controlled my hand trembles. -- Gentlemen take this to heart. I was part of the blind PD trials with Annovis and felt great improvement with the drug. Not knowing at the time if it was a placebo affect, we had to wait for the data to be released. I finally learned from my neurologist today, that I was indeed on the 20 mg dose. I was so happy I teared up. Hopefully they will get all the funding and approvals to bring this to Market asap. FEEL FREE TO REPOST THIS. TODAY IS A GRErAT DAY FOR ME and all parkinsons patients. Stay strong, bhelp is on its way !! With definite improvements like that one on the attached image, one would think that Dr. Maccecchini would have foreign countries beating down her door to partner with her! Note in the second attached image the "NUMBER OF DRUGS IN PIPELINE 2025" and the many "Externally sourced drugs (licensed, acquired, or co-developed) with companies like Pfizer, Novartis, Roche, etc. There are many reasons that Annovis Bio can't advance their work despite the size of their pipeline and the many line items that are ready to advance into Phase 3. Despite Dr. Maccecchini telling investors of low hanging fruit, the ONLY accessible fruit to her is partnering with vulture funding AND your purses and wallets 🐀🏴‍☠️

$ANVS IBIO currently running, its medical

$ANVS i dont know what the fuck is going on. I was in a blind trial in which after its conclusion, i was told I had the 20mg dosage. The drug worked really well ! 0 side effects

$ANVS generates 🥳 🅴🆇🅲🅸🆃🅴🅼🅴🅽🆃 -- Keep the amazing work team. So proud of the company and the results. Let's change the world!!! 🙌 -- Is the plan to try to get FDA approval this month (Oct 2024) still a go?! 📆 -- I would love to try this drug! I am desperate for a cure or way to stop progression. 😰 -- WOW! Major progress in the treatment of neurodegenerative disease. And if the FDA agrees, the drug may be on the market in the semi near future...possibly in 2025. 🗓️ -- Good news. Tks to give us hope. 🤞 -- This drug works and give people hopes! 🙏🏻 Based on my interaction with Dr. Maccecchini her thoughts about Retail investors are that they are amazingly .... Well, for the time being let's note that "FDA approval this month (Oct 2024)" didn't occur. Might "the drug may be on the market in the semi near future ... possibly in 2025"? We still have 2 months before Christmas. Dr. Maccecchini? #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #GoTeamFox #Parkinsons #Research #FindACure #UnityWalk #OutrunPD #NIH #NIA #SEC

The Unsolved Mysteries of $ANVS ... 1. Why some invested in Annovis Bio attack people who voice concerned. Is it because the CEO of the company herself does this against SeekingAlpha authors and even shareholder(s) on this channel? Does or has she requested that other do this?? Has she sent me an email directing me to do the same with full technical support from her office??? [ Is this an example of professionalism and leadership shareholders embrace.] https://stocktwits.com/ReturnOfEsquire/message/606372057 2. In Q4 2024, Dr. Maccecchini launched a video where she projected such high confidence regarding partnerships from multiple foreign countries that she had to apparently bashfully reign herself from saying too much! "

$ANVS I think the next catalyst for ANVS will be AVXL’s approval in Europe. The CHMP recommendation for AVXL could come on November 14th. I think a recommendation would dramatically boost AVXL’s $800 million market cap and have a sympathetic effect on ANVS’s $50 million market cap. At the same time, I think a rejection of AVXL wouldn’t have much downside here.

$ANVS Geeze Fox #4 in your diatribe below….you still hold stock???!!! HAHAHA Speaks volumes!

Truth about $ANVS ... 1. The post I made moments ago was created the other night when Amazon's AWS Service had an outage and that post couldn't be sent with attachments. I just noticed that the post was sent in error without my attachments. I thought about revising the post to reduce any projection of hostility, but I choice to send it "as is" because every part of it to the best of my knowledge is true. 2. I have been supportive and supporting Annovis Bio since 2001 with the false belief that Dr. Maccecchini was actually trying to solve the diseases she states that she is trying to solve. IMO, this is NOT her primary objective. This is based on my personal experience having been invited into her company to assist in refining their message. 3. There is a common belief among some that Dr. Maccecchini is a good scientist, but not a great CEO. She is neither. IMO, this belief system was fostered by Dr. Maccecchini herself with the plethora of paid advertising promoting herself with disguised scientific interviews and articles. Those interviews and articles has been seen by many long-term investor her who haven't done due diligence to quantify if anything that Dr. Maccecchini has stated is actually true. I too fail in this due diligence in a blind hope that Dr. Maccecchini's drug would help patients. It does NOT IMO. Her studies are NOT and have NEVER been robust or well designed. ONLY she says that she great at designing drug studies. NO one else well say this that isn't on her payroll. 4. I don't post here because it is in my self interest. If you buy Dr. Maccecchini's stock and it goes up that's great for me because I still hold this stock. However, telling the truth about Dr. Maccecchini and this company is more important to me because Dr. Maccecchini poaches patients and their families to buy stock. 5. The attached post below mentions, "When you see certain posters show up, you know it's a concerted and likely compensated effort. One is here now, not a coincidence." IMO, this is true because I have witnessed this in Dr. Maccecchini webinars where callers are planted. IMO, this is also true of internet spreadsheets with patient feedback. Dr. Maccecchini is NOT honest with her shareholders. If you disagree I would like to hear what you think it is okay for her to pitch to patients to buy stock, tell her loyal investors that foreign nations will back her, that hundreds of million in dollars are incoming because her data is so great, and on and on .... There were two separate Class Action suits against Dr. Maccecchini in 2021 which were dismissed w/o prejudice. There is still a brief time that those legal actions can be revived. Alternately, if you suffered financial losses in more recent years, please consider exploring legal action. If you do not know how to articulate the information in an out reach to legal counsel, please contact me and I would be happy to draft for you. I have drafted for Dr. Maccecchini, I have made transcriptions for her based on her request for me to do so. Some of the PRs that long-terms investors have seen were products of my work and original thoughts. My contact with Dr. Maccecchini has been numerous with much of it preserved through emails and other forms of communications. These will all be available in the course of any lawsuit against Annovis Bio. #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #GoTeamFox #Parkinsons #Research #FindACure #UnityWalk #OutrunPD #NIH #NIA #SEC

Truth about $ANVS ... CEO, Maria Maccechini @MaccM commented "Alzheimer's disease is multifactorial, and targeting just one of its causes has historically yielded limited therapeutic benefit," and that "What makes buntanetap truly promising is its ability to target multiple neurotoxic proteins simultaneously and interrupt the toxic cascade—something we have long believed was necessary for meaningful progress. These biomarker results validate our preclinical and earlier clinical findings and reinforce our confidence that we are on the right track." in this Oct. 09, 2025 PR: https://www.annovisbio.com/press-release/annovis-announces-novel-biomarker-data-in-alzheimers-patients-supporting-buntanetaps-potential-as-a-disease-modifying-treatment Having witnessed first hand how Dr. Maccecchini operates, I would caution ALL READERS to question the sincerity of any of the information issued by her and her company, Annovis Bio. What is weak in this PR (and why it matters) ⚠️ 1. No effect sizes, confidence intervals, or p-values reported 🚩 - The release lists which markers fell but gives no quantitative magnitude, no statistical testing details, and no multiplicity correction. Without numbers you can’t judge clinical relevance or whether results are likely noise. 2. Short treatment window cited (three months) — too short to prove disease modification 🚩🚩 - Disease-modifying effects in AD are typically demonstrated by sustained changes in clinical outcomes over 12–18+ months, not biomarker shifts at 3 months. The company itself previously signaled an 18-month readout plan for disease-modification claims. Early biomarker trends are hypothesis-generating but do not establish modification. 3. Unclear sample size and selection (risk of post-hoc bias) 🚩🚩🚩 - The PR does not state how many patients contributed biomarker data, whether the analysis population was pre-specified, or whether samples were selected post-hoc (e.g., only responders or only pTau217+). Small or post-hoc subsets can yield misleading “positive” biomarker signals. 4. No independent replication / peer review 🚩🚩🚩🚩 - Results come via company PR; there’s no link to a manuscript, preprint, or independent lab report. That makes independent verification impossible. 5. Clinical relevance not shown 🚩 - Even if biomarkers change, the press release does not connect those changes to clinical benefit (cognition, function) in the same patients — the crucial bridge for disease modification claims is that biomarker changes predict meaningful clinical slowing. The company’s credibility context 👀 Annovis has previously faced investor litigation and criticism alleging it misrepresented trial results (class actions filed in 2021), and its AD program has had high-profile setbacks where trials missed primary endpoints and stock fell sharply. That history increases the need for independent, fully transparent data rather than headline PR claims. Key references: class action/investor-investigation pages and major press reporting on missed endpoints and large stock moves. Early biomarker reductions at 3 months are interesting but far from proof of disease modification. Given Annovis’s prior investor litigation and mixed trial record, independent data (full datasets, pre-specified analyses, peer review) is essential before 🤥 accepting the claim. This company PR is pure fluff w/o scientific rigor for the sole purpose of drawing in more novice investors or people with loved ones affected by the diseases that Dr. Maccecchini says that she can cure ... but, most likely cannot. If the purpose of the PR is to bring in funding, then do so w/o abusing Retail investors. Bring to fruition the various foreign countries across multiple continents you stated on video would be interested in partnering to support your Phase 3 drug studies. You, Dr. Maccecchini, are the one making grandiose and unproven claims along with your Chairman of the Board, Michael Hoffman, about 200M+ in private funding, 40M in NIA funds, and patients arising from wheelchairs ... Stop telling patients and their families to buy your stock during your company's "Live Patient's Forum". Stop inserting fake patients in your drug studies who go online and say that they are getting well even though other patients are noting no effect. Stop holding webinars with pre-planted callers bottle-feeding investors listening to the call to falsely believe that funding would not be a problem given all your great data. As @Carl_K commented, "Ethics and honesty last longer" ... attributes I have yet to see. "CEO , at a $29M MC, meanwhile also not in listing compliance, congratulates her CFO. Wait, which one. April 29, 2024: announcement of failed AD results. One day later (!!), CFO 'resignation'. s3.amazonaws.com/sec.irpass... Sep. 2024 new interim CFO - March 27, 2025 'resignation' of CEO. ca.marketscreener.com/quote... Yesterday's quotes: lies and stupidity: "Ideally you want to develop a drug that works and give it free to the whole world. Now realistically I need millions of dollars hundreds of millions of dollars to make the drug to get the drug approved to get it through the FDA to test it. [...] But realistically the people that give me money want money. If I had known how much it took maybe I wouldn't have done it. [...] The most important thing was to find a good chief financial officer with public knowledge, because I could have never never in my wildest dreams done all the financial paperwork that he did." https://stocktwits.com/Carl_K/message/609888870 Comments from @ReturnOfEsquire @Jwa68 and @Bigmike50 on that thread were all spot on! You are shooting in the dark with investor capital as part of your lifestyle with a minuscule possibility of success. Your company has faced criticism and skepticism regarding its statistical methodology and data management in subsequent trials. The likelihood of more missed endpoints and problems with data analysis will continue. You play the edges and use dubious interpretations to lured in Retail investors which no sophisticated entities will never fall victim to and certainly would never enter into a meaningful transactional discussion with your company. This is ALL based on false possibilities. Why else would you state that you would dilute down to 30¢ a share last year??? #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info#GoTeamFox #Parkinsons #Research #FindACure #UnityWalk #OutrunPD #NIH #NIA #SEC

$ANVS Interesting John's Hopkins team thinks Lag-3 and/or Aplp1 surface proteins as partially responsible for transferring bad alpha-syn from neuron to neuron and shares success of slowing down progression of PD with antibody attached to Aplp1. And near the it begs the question of how "The Johns Hopkins researchers are also looking into how they could prevent unhealthy cells from releasing disease-causing alpha-synuclein in the first place." My answer is Buntanetap!! https://www.hopkinsmedicine.org/news/newsroom/news-releases/2024/06/new-study-suggests-cancer-drug-could-be-used-to-target-protein-connection-that-spurs-parkinsons-disease

$ANVS look at the call options for next week and tell me news ain’t coming out lol